Advanced search
Publication Cover
Hematology Volume 18, 2013 - Issue 6
Submit an article Journal homepage
586
Views
6
CrossRef citations to date
0
Altmetric
ACUTE LEUKEMIA

Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia

Alireza ArdjmandCancer Research UnitSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia; and Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
,
Charles E. de BockCancer Research UnitSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia; and Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
,
Somayeh ShahrokhiDepartment of ImmunologySchool of Medicine, Lorestan University of Medical Sciences, Khorramabaad, Iran
,
Lisa F. LinczHunter Medical Research InstituteNew Lambton Heights, New South Wales, Australia; and Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
,
Andrew W. BoydLeukaemia Foundation of Queensland Research Unit, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
,
Gordon F. BurnsCancer Research UnitSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
&
Rick F. ThorneCancer Research UnitSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia; and Hunter Medical Research Institute, New Lambton Heights, New South Wales, AustraliaCorrespondence[email protected]
 show all
Pages 315-322 | Published online: 15 Nov 2013

References

  • Campana D. Minimal residual disease studies in acute leukemia. Am J Clin Pathol. 2004;122( Suppl):S47–57.
  • Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115:4657–63.
  • Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Educ Program. 2010;2010:7–12.
  • Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol/Oncol Clin North Am. 2009;23:1083–98, vii.
  • Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24:521–35.
  • Germano G, del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A, et al. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia. 2003;17:1573–82.
  • Guggemos A, Eckert C, Szczepanski T, Hanel C, Taube T, van der Velden VH, et al. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia. Haematologica. 2003;88:737–46.
  • Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117:6267–76.
  • de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, et al. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. Leukemia. 2012;26:918–26.
  • Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118:5218–26.
  • Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia. 2010;24:491–9.
  • Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108:711–17.
  • Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood. 1991;77:1717–22.
  • Pfaffl MW. Quantification strategies in real time PCR. In: , Bustin SA, (ed.) A-Z of quantitative PCR. La Jolla, CA: International University Line; 2004. pp.87–112.
  • Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115–20.
  • Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118:149–61.
  • Tohmiya Y, Koide Y, Fujimaki S, Harigae H, Funato T, Kaku M, et al. Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia. Tohoku J Exp Med. 2004;204:125–33.
  • van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11.
  • Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM, et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia. 2003;17:1324–32.
  • Sandoval J, Heyn H, Mendez-Gonzalez J, Gomez A, Moran S, Baiget M, et al. Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia. Br J Haematol. 2013;160:406–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.